EBioMedicine (Sep 2019)

Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer managementResearch in context

  • Kamran A. Ahmed,
  • Casey L. Liveringhouse,
  • Matthew N. Mills,
  • Nicholas B. Figura,
  • G. Daniel Grass,
  • Iman R. Washington,
  • Eleanor E. Harris,
  • Brian J. Czerniecki,
  • Peter W. Blumencranz,
  • Steven A. Eschrich,
  • Jacob G. Scott,
  • Roberto Diaz,
  • Javier F. Torres-Roca

Journal volume & issue
Vol. 47
pp. 163 – 169

Abstract

Read online

Background: Utilizing the linear quadratic model and the radiosensitivity index (RSI), we have derived an expression for the genomically adjusted radiation dose (GARD) to model radiation dose effect. We hypothesize GARD is associated with local recurrence and can be used to optimize individual triple negative breast cancer (TNBC) radiation dose. Methods: TN patients from two independent datasets were assessed. The first cohort consisted of 58 patients treated at 5 European centers with breast conservation surgery followed by adjuvant radiotherapy (RT). The second dataset consisted of 55 patients treated with adjuvant radiation therapy. Findings: In cohort 1, multivariable analysis revealed that as a dichotomous variable (HR: 2.5 95% CI 1–7.1; p = .05), GARD was associated with local control. This was confirmed in the second independent dataset where GARD was the only significant factor associated with local control (HR: 4.4 95% CI 1.1–29.5; p = .04). We utilized GARD to calculate an individualized radiation dose for each TN patient in cohort 2 by determining the physical dose required to achieve the GARD target value (GARD ≥ 21). While 7% of patients were optimized with a dose of 30 Gy, 91% of patients would be optimized with 70 Gy. Interpretation: GARD is associated with local control following whole breast or post-mastectomy radiotherapy (RT) in TN patients. By modeling RT dose effect with GARD, we demonstrate that no single dose is optimal for all patients and propose the first dose range to optimize RT at an individual patient level in TNBC. Keywords: Genomically adjusted radiation dose, Personalized radiotherapy, Radiotherapy, Breast cancer